Permian Resources Announces First Quarter 2025 Earnings Conference Call

Permian Resources Announces First Quarter 2025 Earnings Conference Call

MIDLAND, Texas–(BUSINESS WIRE)–
Permian Resources Corporation (“Permian Resources” or the “Company”) (NYSE: PR) announced today that it will report first quarter 2025 financial and operating results after the market closes for trading on Wednesday, May 7, 2025. Management will host an earnings conference call on Thursday, May 8, 2025 at 9:00 a.m. Central (10:00 a.m. Eastern). Interested parties are invited to participate on the call by dialing (800) 549-8228 (Conference ID: 27785) at least 15 minutes prior to the start of the call or via the internet at www.permianres.com. A replay of the call will be available on the Company’s website or by phone at (888) 660-6264 (Passcode: 27785) for a 14-day period following the call.

About Permian Resources

Headquartered in Midland, Texas, Permian Resources is an independent oil and natural gas company focused on driving peer-leading returns through the acquisition, optimization and development of high-return oil and natural gas properties. The Company’s assets are located in the Permian Basin, with a concentration in the core of the Delaware Basin. Through its approximately 450,000 net acres in West Texas and Southeast New Mexico, Permian Resources is the second largest Permian Basin pure-play E&P. For more information, please visit www.permianres.com.

Hays Mabry – Vice President, Investor Relations

(432) 315-0114

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo

Prairie Operating Co. Announces 11-Well Development at Rusch Pad

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), today announced the launch of an 11-well development program at the Rusch Pad in Weld County, Colorado. The first well was spud on April 1, 2025, utilizing Precision E-Drilling Rig 461, as part of the Company’s continued strategy to expand production and enhance operational efficiencies in the Denver-Julesburg (“DJ”) Basin.

The Rusch Pad development will consist of eleven two-mile lateral wells, alternating between the Niobrara A, B, and C Chalks and the Codell Sandstone. Drilling is expected to be completed by early June, with hydraulic fracturing commencing shortly after. Initial production is anticipated in early August. To minimize environmental impact, Prairie will deploy Precision’s E-rig 461, powered by natural gas generators with battery backup to enhance efficiency and reduce emissions.

“The Rusch Pad development is an important step in Prairie’s ongoing growth strategy following the closing of the Bayswater acquisition,” said Edward Kovalik, Chairman and CEO of Prairie. “With this new development, we are expanding our production footprint, optimizing our asset base, and further positioning Prairie for long-term success. We remain committed to disciplined capital deployment and maximizing shareholder value.”

The Rusch Pad development follows the recent closing of Prairie’s acquisition of Bayswater assets, which significantly expanded the Company’s position in the DJ Basin. Prairie is currently focused on integrating these assets, capturing operational efficiencies, and executing its development program to drive production growth and cash flow generation.

About Prairie Operating Co.

Prairie Operating Co. is a Houston-based publicly traded independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company’s assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a primary focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation. More information about the Company can be found at www.prairieopco.com.

Forward-Looking Statement

The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  All statements, other than statements of present or historical fact included herein, are forward-looking statements. When used herein, including any oral statements made in connection herewith, the words “strive”, “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. The Company cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. There may be additional risks not currently known by the Company or that the Company currently believes are immaterial that could cause actual results to differ from those contained in the forward-looking statements. Additional information concerning these and other factors that may impact the Company’s expectations can be found in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K/A filed with the SEC on March 6, 2025, and any subsequently filed Quarterly Report and Current Report on Form 8-K. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

Investor Relations Contact:

Wobbe Ploegsma
[email protected] 
832.274.3449



Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program

Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target

Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million

Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and losses

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that Sanofi has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases. The undisclosed target is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program.

“Using our DEL-AI platform, we successfully identified novel binders from which we derived a series of targeted protein degraders and stand-alone target binders for this previously undruggable target,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “This high value target is a transcription factor involved in the regulation of proinflammatory cytokines serving as a central regulator of inflammation response in autoimmune diseases where targeted protein degradation could offer an innovative treatment option.”

“Sanofi’s dedication to this program expands our mutual drug discovery pipeline in autoimmune disease and speaks to the productivity of our collaboration,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. “In addition, the highly novel nature of this target further validates the power of Nurix’s DEL-AI discovery platform to drive the discovery and development of truly innovative drugs. Partnerships are an important part of Nurix’s business model, adding non-dilutive capital and expanding our pipeline by retaining product opt-in rights in the United States. To date, Nurix has received $460 million from partners, including $105 million in payments received from the Sanofi collaboration. We look forward to continuing to advance these programs together with Sanofi, with the shared goal of providing new therapeutic options for patients with autoimmune and inflammatory disorders.”

Under the collaboration agreement, Nurix is deploying its proprietary DEL-AI drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Sanofi has the right to license drug candidates resulting from the work, and Nurix has the option to co-develop and co-promote up to two future products in the United States after studies to assess dosing, efficacy, and safety that provide clinical proof of concept. For those programs for which Nurix exercises its option to co-develop and co-promote, the parties will split U.S profits and losses evenly and Nurix will be eligible to receive royalties on ex-U.S. sales on all optioned products. For programs that Nurix does not exercise its option, Nurix will receive milestones and royalties based on global development and sales. Upon signing the agreement in December 2019, Sanofi made an upfront payment of $55 million to Nurix and one year later paid an additional $22 million to expand the scope of the collaboration. Including this $15 million license extension fee, Nurix has received a total of $105 million from Sanofi as part of this collaboration and remains eligible for up to $465 million in development, regulatory, and commercial milestones per licensed program as well as royalties on future sales.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Forward-Looking Statements

This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s future plans and prospects, including its plans for the Nurix-Sanofi collaboration; the potential benefits of the Nurix-Sanofi collaboration; Nurix’s expectations with respect to the programs described in this press release; the potential achievement of collaboration milestones and license payments; the extent to which targeted protein degraders and stand-alone target binders may address a range of diseases, including autoimmune diseases; and the potential advantages of Nurix’s scientific approach and DEL-AI platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Sanofi collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Sanofi collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Sanofi collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K for the fiscal year ended November 30, 2024, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:

Investors

Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
[email protected]

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
[email protected]

Media

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]



Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR

Bruker Announces Introduction of Revolutionary d-DNP Polarizer for MRI Research and for Dynamic Nuclear Polarization Liquids NMR

First successful customer installation of novel dissolution d-DNP Polarizer at UCSF

SAN FRANCISCO–(BUSINESS WIRE)–Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of this innovative technology has been successfully completed, marking a milestone in hyperpolarized MRI for preclinical research to improve cancer diagnostics and to assess response to treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402925205/en/

Bruker d-DNP polarizer shown (center) at UCSF, between Bruker 9.4T MRI (far left) and Fourier 80 NMR (right of polarizer). The novel d-DNP system enables >10,000x signal gains on 13C in high-field MRI and NMR systems.

Bruker d-DNP polarizer shown (center) at UCSF, between Bruker 9.4T MRI (far left) and Fourier 80 NMR (right of polarizer). The novel d-DNP system enables >10,000x signal gains on 13C in high-field MRI and NMR systems.

Dynamic Nuclear Polarization (DNP) can enhance the sensitivity of Nuclear Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI) by transferring polarization from electron spins to nuclear spins. Dissolution DNP (d-DNP) extends the applicability of DNP to solution-state liquids NMR and to preclinical MRI research. Polarization occurs in a separate 7 Tesla polarizer magnet at temperatures below 1.4 Kelvin, accelerated by Bruker’s proprietary active cross-polarization technology.

Subsequently, the highly polarized frozen sample is ejected, melts and dissolves, achieving sensitivity gains of over 10,000-fold in solution samples near room or body temperatures, enabling the observation of low-abundance nuclei like 13C in real-time. Hyperpolarized MRI using d-DNP is particularly beneficial for in vivo studies of 13C-labelled metabolites, enabling live tracking of chemical conversion to downstream metabolites. This highlights metabolic differences between healthy and diseased tissues for conditions ranging from cancer to cardiac health. It can be used to assess response to treatment in animal models, contributing to understanding drug efficacy and disease mechanisms.

With the novel Bruker d-DNP Polarizer, scientists can conduct previously impossible experiments in chemical or metabolic analysis in NMR and preclinical MRI. Bruker provides a faster d-DNP approach using cross polarization (CP) of 1H and 13C. This patented CP provides 5-10x faster polarization compared to traditional d-DNP of 13C. This new CP technology is a testament to Bruker’s commitment to pushing boundaries and empowering scientists to conduct groundbreaking research.

Professor Renuka Sriram, who leads the preclinical Hyperpolarized Magnetic Resonance Imaging group at UCSF, highlighted the significance: “The Bruker d-DNP Polarizer is a pivotal new tool for our research team. This will enable us to explore metabolic pathways that are only accessible with dissolution DNP. Bruker’s much faster CP-based d-DNP technology and automated d-DNP system further enhance our ability to develop diagnostics for cancers and other metabolic conditions.”

Professor Dan Vigneron, Director of the Hyperpolarized Imaging Center at UCSF, elaborated: “With this advanced d-DNP system, we can accelerate our preclinical research efforts and contribute to the development of more effective diagnostic tools. Our collaboration with Bruker is instrumental in pushing the boundaries of what is possible in hyperpolarized MRI.”

“At Bruker, we are committed to driving innovation in the field of hyperpolarization,” stated Dr. James Kempf, Senior Manager DNP & Hyperpolarization at Bruker BioSpin. “The installation of our d-DNP Polarizer at UCSF exemplifies our dedication to advancing scientific research, and it also highlights our partnerships with leading institutions to develop cutting-edge technologies to transform healthcare.”

As the research community begins to harness the capabilities of the Bruker d-DNP Polarizer, the potential for pioneering discoveries in metabolic imaging and disease diagnostics is immense. The collaboration between Bruker and UCSF is set to pave the way for future advancements in hyperpolarized MRI. Additional d-DNP customer installations are already planned in Europe and the US. The UCSF partnership aims to validate the d-DNP technology in oncology applications, including demonstrating the value of the unique higher-throughput cross-polarization d-DNP approach.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Investor Contact:

Joe Kostka

Director – Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

Media Contact:

Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 373-3531

E: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Science Biotechnology Research Oncology Health Medical Devices Health Technology Genetics

MEDIA:

Photo
Photo
Bruker d-DNP polarizer shown (center) at UCSF, between Bruker 9.4T MRI (far left) and Fourier 80 NMR (right of polarizer). The novel d-DNP system enables >10,000x signal gains on 13C in high-field MRI and NMR systems.
Photo
Photo
New d-DNP Polarizer with automated workflows using TopPol software on the touchscreen monitor.
Logo
Logo

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–
Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Each option has an exercise price equal to $8.49 per share, Bicycle Therapeutics’ closing trading price on March 31, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the employees’ continued service relationship with the company through the applicable vesting dates. The awards are subject to the terms and conditions of Bicycle Therapeutics’ 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

[email protected]

857-523-8544

Matthew DeYoung

Argot Partners

[email protected]

212-600-1902

Media:

Jim O’Connell

Weber Shandwick

[email protected]

312-988-2343

KEYWORDS: Europe United States United Kingdom North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Health Technology

MEDIA:

Logo
Logo

Ziff Davis Completes Two Acquisitions in Q1 2025

Ziff Davis Completes Two Acquisitions in Q1 2025

NEW YORK–(BUSINESS WIRE)–
Ziff Davis, Inc. (NASDAQ: ZD), announced today that it completed two acquisitions in the first quarter of 2025.

The acquisitions listed below grow Ziff Davis’ global customer base, provide access to new markets and expand the company’s product lineup.

theSkimm (equity)

Health and Wellness (USA)

Maxroll (asset)

Gaming and Entertainment (Netherlands)

Terms of the individual acquisitions were not disclosed, and the financial impact to Ziff Davis is not expected to be material with respect to the acquisitions.

About Ziff Davis

Ziff Davis (NASDAQ: ZD) is a vertically focused digital media and internet company whose portfolio includes leading brands in technology, shopping, gaming and entertainment, health and wellness, connectivity, cybersecurity, and martech. For more information, visit www.ziffdavis.com.

Source: Ziff Davis, Inc.

Alan Steier

Investor Relations

Ziff Davis, Inc.

[email protected]

Rebecca Wright

Corporate Communications

Ziff Davis, Inc.

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Media Online Entertainment Internet Search Engine Marketing Blogging Technology Digital Marketing Publishing Marketing Advertising Content Marketing Communications

MEDIA:

Logo
Logo

Cognyte Reports Fourth Quarter and Fiscal Year Ended January 31, 2025 Financial Results

Cognyte Reports Fourth Quarter and Fiscal Year Ended January 31, 2025 Financial Results

Double-digit revenue growth and strong year-over-year increase in profitability

Guides to fiscal 2026 revenue of approximately $392 million with a significant increase in profitability

HERZLIYA, Israel–(BUSINESS WIRE)–Cognyte Software Ltd. (NASDAQ: CGNT) (the “Company,” “Cognyte,” “we,” “us” and “our”), a global leader in investigative analytics software, today announced results for the three months and year ended January 31, 2025 (“Q4 FYE25” and “FYE25”).

Financial Summary for Three Months Ended January 31, 2025

  • Q4 FYE25Revenue was $94.5 million, up approximately 13% compared to the same period last year.
  • Q4 FYE25 GAAP operatingincome was $0.7 million, compared to an operating loss of $2.9 million in the same period last year.
  • Q4 FYE25 Non-GAAP operatingincome was $6.0 million, compared to operating income of $1.0 million in the same period last year.
  • Q4 FYE25 GAAP Net loss was$0.2 million, compared to a net loss of $1.9 million in the same period last year.
  • Q4 FYE25 Adjusted EBITDA increased by approximately 114% to $9.3 million, compared to $4.3 million in the same period last year, demonstrating the leverage we have in our financial model.

Financial Summary for the Year Ended January 31, 2025

  • FYE25Revenue was $350.6 million, up approximately 12% compared to last fiscal year.
  • FYE25 GAAPoperating loss was $5.1 million, compared to an operating loss of $18.1 million last fiscal year.
  • FYE25 Non-GAAP operating income improved significantly to $15.7 million, compared to an operating loss of $4.2 million last fiscal year.
  • FYE25 GAAP Net losswas$7.2 million, compared to a net loss of $11.6 million last fiscal year.
  • FYE25 Adjusted EBITDA more than tripledto $29.1 million, compared to $9.0 million last fiscal year.

Balance Sheet and Net Cash Provided by Operating Activities

  • As of January 31, 2025, cash, cash equivalents and restricted cash were $113.1 million, compared to $83.1 million at January 31, 2024.
  • During the three and twelve months ended January 31, 2025, net cash provided by operating activities was $18.7 million and $46.8 million, respectively, compared to net cash provided by operating activities of $9.8 million and $34.6 million, respectively, in the same periods last fiscal year.

Management Commentary

“Our strong performance in fiscal year 2025 speaks to the value our innovation provides and the trust customers place in Cognyte,” said Elad Sharon, Cognyte’s chief executive officer. “Our strategy of deepening relationships with existing customers and expanding into new accounts is reflected in our momentum. We help our customers stay ahead of evolving threats by providing advanced technologies, including AI. We believe Cognyte is well positioned for long-term growth.”

“We closed our fiscal year with another quarter of double-digit revenue growth, significant improvement in profitability and strengthening our balance sheet,” said David Abadi, Cognyte’s chief financial officer. “For fiscal 2026, we expect another year of double-digit revenue growth with profitability growing significantly faster than the top line.”

FYE26 Outlook

Our outlook for the year ending January 31, 2026 (“FYE26” and “Fiscal 2026”) is as follows:

  • Revenue: $392 million at the midpoint with a range of +/-2%, representing approximately 12% growth from previous year revenue.
  • Adjusted EBITDA: Approximately $43 million at the midpoint of our revenue outlook.
  • Non-GAAP Diluted EPS: $0.16 at the midpoint of our revenue outlook.

Additional Financial and Operational Data for the Fourth Quarter and Year Ended January 31, 2025

  • FYE25 Total Software revenue increased by $28.1 million to $306.7 million, compared to last fiscal year, aligned with our growth strategy.
  • Q4 FYE25 and FYE25 Software revenue increased by $6.0 million and by $12.3 million, respectively, compared to the same periods last year. The increase was driven by increased sales of appliance software, perpetual licenses and, to a lesser degree, subscriptions.
  • Q4 FYE25 and FYE25 Software services revenue increased by $3.6 million and $15.8 million, respectively, compared to the same periods last year.
  • Q4 FYE25 and FYE25 Professional services and other revenue increased by $1.2 million and $9.1 million, respectively, compared to the same period last year. The increase during FYE25 was primarily related to the timing and scale of deployments.
  • Q4 FYE25 Recurring Revenue(1) increased by 10.3% to $47.3 million, compared to the same period last year.
  • Q4 FYE25 Non-GAAP Gross profit and margin were $67.6 million and 71.5%, respectively, an increase of $9.8 million and 250 bps improvement compared to the same period last year.
  • Q4 FYE25 Billings(2) were $95.0 million, consistent with last year.
  • Total Backlog(3) at the end of Q4 FYE25 was $415.5 million and short-term Backlog was $227.9 million.
  • Total RPO(4) $545.8 million at the end of Q4 FYE25.
  • Short-term RPO(4) at the end of Q4 FYE25 increased to $335.3 million, providing solid visibility into FYE26 revenue.

For information about the non-GAAP financial measure or key metric, please see “Supplemental Information About Non-GAAP Financial Measures and Other Key Metrics” at the end of this release.

 

(1) Recurring Revenue – Recurring revenue is comprised primarily of revenue from support contracts as well as revenue from subscription offerings.

(2) Billings – Revenue plus the change in contract liabilities, contract assets and unbilled balances.

(3) Backlog represents unbilled amounts contracted under contracts deemed certain to be invoiced.

(4) RPO, or remaining performance obligations, represents contracted revenue that has not yet been recognized that will be invoiced and recognized as revenue in future periods.

Conference Call Information

We will conduct a conference call today at 8:30 a.m. ET to discuss our results for the three months and full year ended January 31, 2025. A real-time webcast of the conference call with presentation slides will be available in the Investor Relations section of Cognyte’s website. Those interested in participating in the question-and-answer session need to register here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call). An archived webcast of the conference call will also be available in the “Investors” section of the company’s website.

Analyst & Investor Day

Cognyte’s senior leadership team will host a virtual Analyst & Investor Day on Tuesday, April 8, 2025, beginning at 8:00 a.m. ET. The event will provide a deeper look into our solutions, the challenges our customers face and how our technology helps them succeed. The event will also feature insights into market dynamics from third-party experts and customers along with our own perspective on industry trends and Cognyte’s positioning. We will also share our long-term financial targets, outlining how we plan to scale revenue and drive profitability. The day will end with a Q&A session. Members of the financial community are encouraged to register for the webcast on Cognyte’s Investor Relations webpage under Upcoming Events. Those interested in participating in the question-and-answer session need to register here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

A webcast replay will be available shortly after the conclusion of the live event.

About Cognyte Software Ltd.

Cognyte is a leading software-led technology company, focused on solutions for data processing and investigative analytics which allow customers to generate actionable intelligence from their data, thereby enabling a safer world. Cognyte’s solutions empower law enforcement, national security, national and military intelligence agencies, and other organizations to navigate an increasingly complex landscape. With offerings that leverage state-of-the-art technology, including Artificial Intelligence (AI), big data analytics and advanced machine learning, Cognyte enables smarter, faster decisions for successful outcomes. Hundreds of customers rely on Cognyte solutions to uncover critical insights from past events and anticipate emerging threats. By harnessing AI-driven intelligence, Cognyte accelerates investigations with exceptional speed and accuracy while enabling customers to better anticipate, predict and mitigate threats with greater precision. Learn more at www.cognyte.com.

About Non-GAAP Financial Measures and Other Key Metrics

This press release and the accompanying tables include non-GAAP financial measures and other key metrics. For a description of these non-GAAP financial measures and other key metrics, including the reasons management uses each measure and metric, and reconciliations of non-GAAP financial measures presented for completed periods to the most directly comparable financial measures prepared in accordance with GAAP, please see the tables below as well as “Supplemental Information About Non-GAAP Financial Measures” at the end of this press release.

Our non-GAAP outlook for FYE26 excludes the following GAAP measures for which we are able to provide a range of probable significance:

  • Stock-based compensation is expected to be between approximately $18.0 and $20.0 million, assuming market prices for our ordinary shares are generally consistent with current levels.

For additional information about our expectations for FYE26, please refer to the Q4 FYE25 conference call we will conduct on April 2, 2025.

Our non-GAAP outlook unless otherwise specified, reflects foreign currency exchange rates approximately consistent with current rates, and does not include the potential impact of any business acquisitions that may close after the date hereof.

We are unable, without unreasonable effort, to provide a reconciliation for other GAAP measures which are excluded from our non-GAAP outlook, including the impact of future business acquisitions or acquisition expenses, future restructuring expenses, and non-GAAP income tax adjustments due to the level of unpredictability and uncertainty associated with these items. For these same reasons, we are unable to assess the probable significance of these excluded items. While historical results may not be indicative of future results, actual amounts for the three months and twelve months ended January 31, 2025, and 2024, respectively, for the GAAP measures excluded from our non-GAAP outlook appear in Table 4 of this press release.

Caution About Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the United States Securities Exchange Act of 1934. Forward-looking statements include statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs, and statements of similar effect relating to Cognyte. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements do not guarantee future performance and are based on management’s expectations that involve a number of known and unknown risks, uncertainties, assumptions and other important factors, any of which could cause our actual results or conditions to differ materially from those expressed in or implied by the forward-looking statements. Some of the factors that could cause our actual results or conditions to differ materially from current expectations include, among others: uncertainties regarding the impact of changes in macroeconomic and/or global conditions; risks related to geopolitical changes and investor visibility constraints; risks related to new tariffs and retaliatory measures that may adversely affect the economy and reduce government spending; risks related to the impact of inflation and related volatility on our financial performance; risks relating to adverse changes to the regulatory constraints to which we are subject; risks related to the impact of disruptions to the global supply chain; risks resulting from health crises; risks related to conditions in Israel including Israel’s conflict with Hamas and other terrorist organizations in the region since October 7, 2023; risks associated with customer concentration and challenges associated with our ability to accurately forecast revenue and expenses; risks associated with political and reputational factors related to our business or operations; risks associated with our ability to keep pace with technological advances and challenges and evolving industry standards; risks relating to proprietary rights infringement claims; risks relating to defects, operational problems, or vulnerability to cyber-attacks of our products or any of the components used in our products; risks related to the strengths of our intellectual property rights protection; risks that we may be unable to establish and maintain relationships with key resellers, partners, and system integrators and risks associated with our reliance on third-party suppliers for certain components, products or services; risks due to the aggressive competition in all of our markets; challenges associated with our long sales cycles and with the sophisticated nature of our solutions; risks associated with our ability or costs to retain, recruit and train qualified personnel; risks relating to our ability to properly manage investments in our business and operations, execute on growth or strategic initiatives; risks associated with acquisitions, strategic investments, partnerships or alliances; risk of security vulnerabilities or lapses, including cyber-attacks, information technology system breaches, failures or disruptions; risks associated with the mishandling or perceived mishandling of sensitive, confidential or classified information; risks associated with our failure to comply with laws; risks associated with our credit facilities or that we may experience liquidity or working capital issues and related risks that financing sources may be unavailable to us on reasonable terms; risks associated with changing tax laws and regulations, tax rates, and the continuing availability of expected tax benefits in the countries in which we operate; risks associated with our significant international operations, including due to our Israeli operations, fluctuations in foreign exchange rates, and exposure to regions subject to political or economic instability; risks associated with complex and changing regulatory environments relating to our operations and the markets we operate in; risks relating to the adequacy of our existing infrastructure, systems, processes, policies, procedures, internal controls and personnel for our current and future operations and reporting needs; risks related to the tax treatment of our spin-off from Verint; risks related to our share repurchase program, and risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer; and other risks set forth and in Section 3.D – “Risk Factors” in our latest annual report on Form 20-F for the fiscal year ended January 31, 2025, being filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2025, and in our subsequent filings with the SEC. In addition, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time. It is not possible for our management to predict all risks and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements that we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Any forward-looking statement made in this press release speaks only as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or any other reason.

 

Table 1

COGNYTE SOFTWARE LTD.

Condensed Consolidated Statements of Operations

 

 

 

Year Ended

January 31,

 

Three Months Ended

January 31,

 

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

(in thousands except per share data)

 

(Audited)

 

(Audited)

 

(Unaudited)

 

(Unaudited)

Revenue:

 

 

 

 

 

 

 

 

Software

 

$

125,815

 

 

$

113,541

 

 

$

37,435

 

 

$

31,440

 

Software service

 

 

180,872

 

 

 

165,027

 

 

 

45,914

 

 

 

42,314

 

Professional service and other

 

 

43,945

 

 

 

34,836

 

 

 

11,156

 

 

 

9,937

 

Total revenue

 

 

350,632

 

 

 

313,404

 

 

 

94,505

 

 

 

83,691

 

Cost of revenue:

 

 

 

 

 

 

 

 

Software

 

 

19,988

 

 

 

18,919

 

 

 

6,173

 

 

 

6,565

 

Software service

 

 

45,184

 

 

 

43,305

 

 

 

11,833

 

 

 

10,407

 

Professional service and other

 

 

38,538

 

 

 

35,776

 

 

 

9,460

 

 

 

9,366

 

Total cost of revenue

 

 

103,710

 

 

 

98,000

 

 

 

27,466

 

 

 

26,338

 

Gross profit

 

 

246,922

 

 

 

215,404

 

 

 

67,039

 

 

 

57,353

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development, net

 

 

108,274

 

 

 

107,283

 

 

 

28,077

 

 

 

27,035

 

Selling, general and administrative

 

 

143,516

 

 

 

125,784

 

 

 

38,225

 

 

 

33,052

 

Amortization of other acquired intangible assets

 

 

258

 

 

 

391

 

 

 

40

 

 

 

120

 

Total operating expenses

 

 

252,048

 

 

 

233,458

 

 

 

66,342

 

 

 

60,207

 

Operating (loss) income

 

 

(5,126

)

 

 

(18,054

)

 

 

697

 

 

 

(2,854

)

Other income (expenses), net:

 

 

 

 

 

 

 

 

Interest income

 

 

2,470

 

 

 

1,896

 

 

 

697

 

 

 

563

 

Interest expense

 

 

(100

)

 

 

(16

)

 

 

(41

)

 

 

(4

)

Other (expenses) income, net:

 

 

(1,614

)

 

 

2,915

 

 

 

(1,628

)

 

 

(3,696

)

Total other income (expenses), net

 

 

756

 

 

 

4,795

 

 

 

(972

)

 

 

(3,137

)

Loss before provision for income taxes

 

 

(4,370

)

 

 

(13,259

)

 

 

(275

)

 

 

(5,991

)

Provision (benefit) for income taxes

 

 

2,864

 

 

 

(1,614

)

 

 

(59

)

 

 

(4,114

)

Net loss

 

 

(7,234

)

 

 

(11,645

)

 

 

(216

)

 

 

(1,877

)

Net income attributable to noncontrolling interest

 

 

4,817

 

 

 

3,925

 

 

 

1,012

 

 

 

737

 

Net loss attributable to Cognyte Software Ltd.

 

$

(12,051

)

 

$

(15,570

)

 

$

(1,228

)

 

$

(2,614

)

 

 

 

 

 

 

 

 

 

Net loss per share attributable to Cognyte Software Ltd.:

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.17

)

 

$

(0.22

)

 

$

(0.02

)

 

$

(0.04

)

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

 

71,797

 

 

 

70,081

 

 

 

72,406

 

 

 

70,905

 

 

Table 2

COGNYTE SOFTWARE LTD.

Condensed Consolidated Balance Sheets

 

 

 

January 31,

 

January 31,

 

 

 

2025

 

 

 

2024

 

(in thousands)

 

(Audited)

 

(Audited)

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

112,719

 

 

$

74,477

 

Restricted cash and cash equivalents and restricted bank time deposits

 

 

381

 

 

 

8,666

 

Accounts receivable, net of allowance for credit losses of $1.1 million and $2.7 million as of January 31, 2025 and 2024, respectively

 

 

109,374

 

 

 

113,260

 

Contract assets, net of allowance for credit losses of $1.0 million and $1.4 million as of January 31, 2025 and 2024, respectively

 

 

6,941

 

 

 

8,859

 

Inventories

 

 

18,988

 

 

 

24,584

 

Prepaid expenses and other current assets

 

 

37,750

 

 

 

35,135

 

Total current assets

 

 

286,153

 

 

 

264,981

 

Property and equipment, net

 

 

28,316

 

 

 

24,384

 

Operating lease right-of-use assets

 

 

35,214

 

 

 

33,833

 

Goodwill

 

 

126,148

 

 

 

126,563

 

Intangible assets, net

 

 

 

 

 

258

 

Deferred income taxes

 

 

3,094

 

 

 

2,928

 

Other assets

 

 

18,895

 

 

 

19,135

 

Total assets

 

$

497,820

 

 

$

472,082

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

25,216

 

 

$

20,863

 

Accrued expenses and other current liabilities

 

 

86,694

 

 

 

75,826

 

Contract liabilities

 

 

107,451

 

 

 

93,778

 

Total current liabilities

 

 

219,361

 

 

 

190,467

 

Long-term contract liabilities

 

 

22,868

 

 

 

29,362

 

Deferred income taxes

 

 

1,006

 

 

 

1,964

 

Operating lease liabilities

 

 

29,806

 

 

 

27,950

 

Other liabilities

 

 

7,676

 

 

 

7,606

 

Total liabilities

 

 

280,717

 

 

 

257,349

 

Commitments and Contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Common stock – $0 par value; Authorized 300,000,000 shares. Issued 72,642,930 and 70,996,535 at January 31, 2025 and January 31, 2024, respectively; Outstanding 72,057,202 and 70,996,535 shares at January 31, 2025 and January 31, 2024, respectively

 

 

 

 

 

 

Additional paid-in capital

 

 

374,126

 

 

 

355,097

 

Treasury stock, at cost 585,728 and 0 shares at January 31, 2025 and January 31, 2024, respectively

 

 

(5,276

)

 

 

 

Accumulated deficit

 

 

(156,643

)

 

 

(144,592

)

Accumulated other comprehensive loss

 

 

(14,015

)

 

 

(12,630

)

Total Cognyte Software Ltd. stockholders’ equity

 

 

198,192

 

 

 

197,875

 

Noncontrolling interest

 

 

18,911

 

 

 

16,858

 

Total stockholders’ equity

 

 

217,103

 

 

 

214,733

 

Total liabilities and stockholders’ equity

 

$

497,820

 

 

$

472,082

 

 

Table 3

COGNYTE SOFTWARE LTD.

Condensed Consolidated Statements of Cash Flows

(Audited)

 

 

 

Year Ended

January 31,

(in thousands)

 

 

2025

 

 

 

2024

 

Cash flows from operating activities:

 

 

 

 

Net loss

 

$

(7,234

)

 

$

(11,645

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

13,652

 

 

 

13,816

 

Allowance for credit losses

 

 

1,416

 

 

 

2,508

 

Gain from business divestiture

 

 

 

 

 

(4,768

)

Stock-based compensation, excluding cash-settled awards

 

 

19,029

 

 

 

12,167

 

Benefit from deferred income taxes

 

 

(1,356

)

 

 

(3,196

)

Non-cash (gains) losses on derivative financial instruments, net

 

 

(179

)

 

 

330

 

Other non-cash items, net

 

 

32

 

 

 

(685

)

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

10,573

 

 

 

12,436

 

Contract assets

 

 

(6,722

)

 

 

(7,340

)

Inventories

 

 

4,570

 

 

 

(960

)

Prepaid expenses and other assets

 

 

(7,804

)

 

 

5,307

 

Accounts payable and accrued expenses

 

 

14,294

 

 

 

4,332

 

Contract liabilities

 

 

7,962

 

 

 

13,897

 

Other liabilities

 

 

(1,552

)

 

 

(2,904

)

Other, net

 

 

101

 

 

 

1,266

 

Net cash provided by operating activities

 

 

46,782

 

 

 

34,561

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

Purchases of property and equipment

 

 

(10,587

)

 

 

(7,035

)

Purchases of short-term investments

 

 

 

 

 

(58,695

)

Maturities of short-term investments

 

 

 

 

 

75,906

 

Settlements of derivative financial instruments not designated as hedges

 

 

117

 

 

 

(977

)

Cash paid for capitalized software development costs

 

 

(2,601

)

 

 

(2,034

)

Proceeds from Business divestiture, net of cost

 

 

4,943

 

 

 

4,975

 

Change in restricted bank time deposits, including long-term portion

 

 

2,437

 

 

 

(2,782

)

Net cash (used in) provided by investing activities

 

 

(5,691

)

 

 

9,358

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

Dividends paid to noncontrolling interest

 

 

(2,577

)

 

 

(2,452

)

Purchases of treasury stock

 

 

(5,276

)

 

 

 

Repayment of principal portion of finance lease liability

 

 

(99

)

 

 

 

Net cash used in financing activities

 

 

(7,952

)

 

 

(2,452

)

Foreign currency effects on cash, cash equivalents, restricted cash, and restricted cash equivalents

 

 

(631

)

 

 

(115

)

Net increase in cash, cash equivalents, restricted cash and restricted cash equivalents

 

 

32,508

 

 

 

41,352

 

Cash, cash equivalents, restricted cash, and restricted cash equivalents, beginning of period

 

 

80,396

 

 

 

39,044

 

Cash, cash equivalents, restricted cash, and restricted cash equivalents, end of period

 

$

112,904

 

 

$

80,396

 

 

 

 

 

 

Reconciliation of cash, cash equivalents, restricted cash and restricted cash equivalents at end of period:

 

 

 

 

Cash and cash equivalents

 

$

112,719

 

 

$

74,477

 

Restricted cash and cash equivalents included in restricted cash and cash equivalents and restricted bank time deposits

 

 

185

 

 

 

5,825

 

Restricted cash and cash equivalents included in other assets

 

 

 

 

 

94

 

Total cash, cash equivalents, restricted cash, and restricted cash equivalents

 

$

112,904

 

 

$

80,396

 

 

Table 4

COGNYTE SOFTWARE LTD.

Reconciliation of GAAP to Non-GAAP Measures

(Unaudited)

 

 

 

Year Ended

January 31,

 

Three Months Ended

January 31,

(in thousands, except per share data)

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Operating income (loss), operating margin and adjusted EBITDA

GAAP Operating (loss) income

 

$

(5,126

)

 

$

(18,054

)

 

$

697

 

 

$

(2,854

)

GAAP operating margin

 

 

(1.5

)%

 

 

(5.8

)%

 

 

0.7

%

 

 

(3.4

)%

Stock-based compensation expenses

 

 

19,029

 

 

 

12,167

 

 

 

5,269

 

 

 

3,976

 

Restructuring expenses, net

 

 

226

 

 

 

1,424

 

 

 

17

 

 

 

(484

)

Legal expenses

 

 

958

 

 

 

287

 

 

 

74

 

 

 

287

 

Other adjustments

 

 

662

 

 

 

(59

)

 

 

(20

)

 

 

64

 

Non-GAAP operating income (loss)

 

$

15,749

 

 

$

(4,235

)

 

$

6,037

 

 

$

989

 

Depreciation and amortization

 

 

13,365

 

 

 

13,238

 

 

 

3,221

 

 

 

3,342

 

Adjusted EBITDA

 

$

29,114

 

 

$

9,003

 

 

$

9,258

 

 

$

4,331

 

Non-GAAP operating margin

 

 

4.5

%

 

 

(1.4

)%

 

 

6.4

%

 

 

1.2

%

Adjusted EBITDA margin

 

 

8.3

%

 

 

2.9

%

 

 

9.8

%

 

 

5.2

%

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Cognyte Software Ltd. reconciliation

GAAP Net loss attributable to Cognyte Software Ltd.

 

$

(12,051

)

 

$

(15,570

)

 

$

(1,228

)

 

$

(2,614

)

Stock-based compensation expenses

 

 

19,029

 

 

 

12,167

 

 

 

5,269

 

 

 

3,976

 

Non-GAAP tax adjustments (footnote 2)

 

 

(4,203

)

 

 

(8,560

)

 

 

(2,134

)

 

 

(5,814

)

Restructuring expenses, net

 

 

226

 

 

 

1,424

 

 

 

17

 

 

 

(484

)

Legal expenses

 

 

958

 

 

 

287

 

 

 

74

 

 

 

287

 

Business divestiture

 

 

29

 

 

 

(4,559

)

 

 

 

 

 

(371

)

Other Non-GAAP adjustments

 

 

645

 

 

 

(289

)

 

 

(20

)

 

 

70

 

Total adjustments (footnote 2)

 

 

16,684

 

 

 

470

 

 

 

3,206

 

 

 

(2,336

)

Non-GAAP Net income (loss) attributable to Cognyte Software Ltd. (footnote 2)

 

$

4,633

 

 

$

(15,100

)

 

$

1,978

 

 

$

(4,950

)

 

 

 

 

 

 

 

 

 

Table comparing GAAP and Non-GAAP diluted net loss per share attributable to Cognyte Software Ltd.

GAAP diluted net loss per share attributable to Cognyte Software Ltd.

 

$

(0.17

)

 

$

(0.22

)

 

$

(0.02

)

 

$

(0.04

)

Non-GAAP diluted net income (loss) per share attributable to Cognyte Software Ltd. (footnote 2)

 

$

0.06

 

 

$

(0.22

)

 

$

0.03

 

 

$

(0.07

)

GAAP weighted-average shares used in computing diluted net loss per share attributable to Cognyte Software Ltd.

 

 

71,797

 

 

 

70,081

 

 

 

72,406

 

 

 

70,905

 

Non-GAAP diluted weighted-average shares used in computing net income (loss) per share attributable to Cognyte Software Ltd. (footnote 2)

 

 

73,508

 

 

 

70,081

 

 

 

74,878

 

 

 

70,905

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

Cost of revenue

 

$

2,079

 

 

$

1,415

 

 

$

573

 

 

$

421

 

Research and development, net

 

 

1,633

 

 

 

2,232

 

 

 

380

 

 

 

483

 

Selling, general, and administrative

 

 

15,317

 

 

 

8,520

 

 

 

4,316

 

 

 

3,072

 

Total stock-based adjustments

 

$

19,029

 

 

$

12,167

 

 

$

5,269

 

 

$

3,976

 

 

 

 

 

 

 

 

 

 

Restructuring expenses, net

 

 

 

 

 

 

 

 

Cost of revenue

 

$

1

 

 

$

106

 

 

$

1

 

 

$

 

Research and development, net

 

 

123

 

 

 

160

 

 

 

 

 

 

 

Selling, general, and administrative

 

 

102

 

 

 

1,158

 

 

 

16

 

 

 

(484

)

Total restructuring adjustments

 

$

226

 

 

$

1,424

 

 

$

17

 

 

$

(484

)

 

 

 

 

 

 

 

 

 

Others Non-GAAP adjustments

 

 

 

 

 

 

 

 

Revenue

 

$

 

 

$

112

 

 

$

 

 

$

 

Selling, general, and administrative

 

 

387

 

 

 

(792

)

 

 

(60

)

 

 

(50

)

Amortization of other acquired intangible assets

 

 

258

 

 

 

391

 

 

 

40

 

 

 

120

 

Total Other adjustments

 

$

645

 

 

$

(289

)

 

$

(20

)

 

$

70

 

 

 

 

 

 

 

 

 

 

Footnotes

(1) The actual cash tax paid, net of refunds, was $1.6 million and $7.2 million for the three months and year ended January 31, 2025, respectively and $2.4 million and $6.8 million for the three months and year ended January 31, 2024, respectively.

(2) The non-GAAP income tax adjustments for the quarter reflects a change in calculating our non-GAAP income taxes from a cash basis (income taxes we expect to pay in the current year) to an accrual basis, as detailed further under “supplemental information about Non-GAAP financial measures” – “non-GAAP income tax adjustments”. Prior period comparative numbers were adjusted accordingly. The non-GAAP income tax provision, non-GAAP net loss attributable to Cognyte Software Ltd. and non-GAAP diluted net loss per share attributable to Cognyte Software Ltd. under the previous method of calculation, which was presented in last year’s press release filing on April 9, 2024, were $6.8 million, $(14.9) million and $(0.21) for the year ended January 31, 2024 and $13.1 million, $(16.4) million and $(0.23) for the three months ended January 31, 2024.

Cognyte Software Ltd. and Subsidiaries

Supplemental Information About Non-GAAP Financial Measures and Other Key Metrics

Non-GAAP Financial Measures

The press release includes reconciliations of certain financial measures not prepared in accordance with GAAP, consisting of non-GAAP operating (loss) income and operating margins, non-GAAP net (loss) income attributable to Cognyte, adjusted EBITDA and adjusted EBITDA margin, non-GAAP diluted net (loss) income per share attributable to Cognyte and non-GAAP diluted weighted-average shares used in computing such measure. The tables above include a reconciliation of each non-GAAP financial measure for completed periods presented in this press release to the most directly comparable GAAP financial measure.

We believe these non-GAAP financial measures, used in conjunction with the corresponding GAAP measures, provide investors with useful supplemental information about the financial performance of our business by:

  • facilitating the comparison of our financial results and business trends between periods, by excluding certain items that either can vary significantly in amount and frequency, are based upon subjective assumptions, or in certain cases are unplanned for or difficult to forecast,
  • facilitating the comparison of our financial results and business trends with other software companies who publish similar non-GAAP measures, and
  • allowing investors to see and understand key supplementary metrics used by our management to run our business, including for budgeting and forecasting, resource allocation, and compensation matters.

We also make these non-GAAP financial measures available because our management believes they provide meaningful information about the financial performance of our business and are useful to investors for informational and comparative purposes.

Non-GAAP financial measures should not be considered in isolation as substitutes for, or superior to, comparable GAAP financial measures. The non-GAAP financial measures we present have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP, and these non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. These non-GAAP financial measures do not represent discretionary cash available to us to invest in the growth of our business, and we may in the future incur expenses similar to or in addition to the adjustments made in these non-GAAP financial measures. Other companies may calculate similar non-GAAP financial measures differently than we do, limiting their usefulness as comparative measures.

Our non-GAAP financial measures are calculated by making the following adjustments to our GAAP financial measures:

Stock-based compensation expenses. We exclude stock-based compensation expenses related to restricted stock awards, stock bonus programs, bonus share programs, and other stock-based awards from our non-GAAP financial measures. We evaluate our performance both with and without these measures because stock-based compensation is typically a non-cash expense and can vary significantly over time based on the timing, size and nature of awards granted, and is influenced in part by certain factors which are generally beyond our control, such as the volatility of the price of our ordinary shares. In addition, measurement of stock-based compensation is subject to varying valuation methodologies and subjective assumptions, and therefore we believe that excluding stock-based compensation from our non-GAAP financial measures allows for meaningful comparisons of our current operating results to our historical operating results and to other companies in our industry.

Restructuring expenses. We exclude restructuring expenses from our non-GAAP financial measures, which include employee termination costs, facility exit costs, certain professional fees, asset impairment charges, and other costs directly associated with resource realignments incurred in reaction to changing strategies or business conditions. All of these costs can vary significantly in amount and frequency based on the nature of the actions as well as the changing needs of our business and we believe that excluding them provides easier comparability of pre- and post-restructuring operating results.

Other adjustments. We exclude from our non-GAAP financial measures fair value adjustments related to revenue acquired in a business acquisition, amortization of acquired technology and other acquired intangible assets, acquisition expenses (benefit), separation expenses, business divestiture gain/losses, provision for legal claim, rent expense for redundant facilities, gains on change in fair value of equity investment, gains or losses on sales of property and certain professional fees unrelated to our ongoing operations.

Non-GAAP income tax adjustments. We exclude our GAAP provision (benefit) for income taxes from our non-GAAP measures of net income attributable to Cognyte Software Ltd., and instead include a non-GAAP provision for income taxes. Cognyte uses a full-year non-GAAP tax rate to compute the non-GAAP tax provision. This full-year non-GAAP tax rate is based on Cognyte’s annual GAAP income, adjusted to exclude non-GAAP items, as well as the effects of significant non-recurring and period-specific tax items which vary in size and frequency. This annual non-GAAP tax rate is based on an evaluation of our historical and projected profit before tax, taking into account the impact of non-GAAP adjustments, tax law changes, as well as other factors such as our current tax structure, existing tax positions and expected recurring tax incentives. Our GAAP effective income tax rate can vary significantly from year to year as a result of tax law changes, settlements with tax authorities, changes in the geographic mix of earnings including acquisition activity, changes in the projected realizability of deferred tax assets, and other unusual or period-specific events, all of which can vary in size and frequency. We believe that our non-GAAP effective income tax rate removes much of this variability and facilitates meaningful comparisons of operating results across periods. We evaluate our non-GAAP effective income tax rate on an ongoing basis, and it can change from time to time. Our non-GAAP income tax rate can differ materially from our GAAP effective income tax rate.

Adjusted EBITDA. Adjusted EBITDA is a non-GAAP measure defined as net income (loss) attributable to non-controlling interest before interest expense, interest income, income taxes, depreciation expense, amortization expense, revenue adjustments, restructuring expenses, acquisition expenses, and other expenses excluded from our non-GAAP financial measures as described above. We believe that adjusted EBITDA is also commonly used by investors to evaluate operating performance between companies because it helps reduce variability caused by differences in capital structures, income taxes, stock-based compensation accounting policies, and depreciation and amortization policies.

Other Key Metrics

Recurring revenue. Cognyte calculates recurring revenue for a period by combining revenue from initial and renewal support, subscription software licenses, and cloud-based SaaS in certain transactions. Recurring revenue is the portion of our revenue that we believe is likely to be renewed in the future. The recurrence of these revenue streams in future periods depends on a number of factors including contractual periods and customers’ renewal decisions. Cognyte believes that recurring revenue provides investors more visibility into our recurring business in the upcoming years and helpful measurement of Cognyte’s potential revenue. Cognyte does not consider recurring revenue to be a non-GAAP financial measure because it is calculated using GAAP revenue.

Billings. Cognyte calculates billings for a period by adding changes in contract liabilities, contract assets and unbilled balances in that period to revenue. Cognyte believes that billings help investors better understand sales activity and ongoing business for a particular period, which is not necessarily reflected in revenue. Billings fluctuate from quarter to quarter. Cognyte does not consider billings to be a non-GAAP financial measure because it is calculated using exclusively revenue, contract liabilities, contract assets and unbilled balances, all of which are financial measures calculated in accordance with GAAP.

Total Backlog and Short-Term Backlog. Backlog is defined as unbilled amounts contracted under contracts deemed certain to be invoiced and recognized as revenue in future periods. Short-term backlog represents backlog that Cognyte expects to be recognized as revenue within the subsequent 12 months. Cognyte monitors backlog to provide visibility into our future revenue. Cognyte does not consider backlog to be a non-GAAP financial measure because it is calculated using exclusively unbilled contracted amounts.

Total Remaining Performance Obligations (RPO) and Short-Term RPO. RPO consist of backlog plus contract liabilities. RPO represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods. The majority of our arrangements are for periods of up to three years, with a significant portion being one year or less. The timing and amount of revenue recognition for our RPO is influenced by several factors, including timing of support renewals, revenue recognition for certain projects that can extend over longer periods of time, delivery under which, for various reasons, may be delayed, modified, or canceled. Therefore, the amount of remaining obligations may not be a meaningful indicator of future results. In some cases, we may decide to cancel outstanding orders and reduce the RPO when there have been extended delays by customers in paying the agreed upon down payments or due to other reasons. Short-term RPO represents RPO that Cognyte expects to be recognized as revenue within the subsequent 12 months. Cognyte monitors RPO to provide visibility into our future revenue. Cognyte does not consider RPO to be a non-GAAP financial measure because it is calculated in accordance with GAAP, specifically under ASC Topic 606.

Investor Relations Contact

Dean Ridlon

Cognyte Software Ltd.

[email protected]

KEYWORDS: Israel Middle East

INDUSTRY KEYWORDS: Software Banking Professional Services Fintech Data Management Technology Artificial Intelligence Security Data Analytics Finance Consulting Telecommunications

MEDIA:

Logo
Logo

Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.  

About Generation Bio

Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.

For more information, please visit www.generationbio.com.

Investors and Media Contact

Maren Killackey
Generation Bio
[email protected]
857-371-4638



YieldMax™ ETFs Announces Distributions on FIAT (127.21%), CVNY (100.49%), ULTY (77.62%), CONY (73.33%), YMAX (68.44%) and Others

CHICAGO and MILWAUKEE and NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) — YieldMax™ today announced distributions for the YieldMax™ Weekly Payers and Group C ETFs listed in the table below.

ETF
Ticker



1

ETF Name Distribution
Frequency
Distribution
per Share
Distribution
Rate



2,4

30-Day

SEC Yield


3

ROC


5

Ex-Date &
Record Date
Payment
Date
GPTY YieldMax™ AI & Tech Portfolio Option Income ETF
Weekly
$0.2668 34.84% 0.00% 100.00% 4/3/25 4/4/25
LFGY YieldMax™ Crypto Industry & Tech Portfolio Option Income ETF
Weekly
$0.4189 60.57% 0.00% 100.00% 4/3/25 4/4/25
QDTY YieldMax™ Nasdaq 100 0DTE Covered Call ETF
Weekly
$0.2638 31.00% 0.00% 37.26% 4/3/25 4/4/25
RDTY YieldMax™ R2000 0DTE Covered Call ETF
Weekly
$0.3351 36.44% 0.00% 78.96% 4/3/25 4/4/25
SDTY YieldMax™ S&P 500 0DTE Covered Call ETF
Weekly
$0.2723 31.10% 0.00% 65.95% 4/3/25 4/4/25
ULTY YieldMax™ Ultra Option Income Strategy ETF
Weekly
$0.0916 77.62% 2.21% 97.00% 4/3/25 4/4/25
YMAG YieldMax™ Magnificent 7 Fund of Option Income ETFs
Weekly
$0.0971 33.26% 69.89% 28.54% 4/3/25 4/4/25
YMAX YieldMax™ Universe Fund of Option Income ETFs
Weekly
$0.1781 68.44% 96.57% 0.00% 4/3/25 4/4/25
ABNY YieldMax™ ABNB Option Income Strategy ETF Every 4 Weeks $0.3665 37.87% 3.62% 0.00% 4/3/25 4/4/25
AMDY YieldMax™ AMD Option Income Strategy ETF Every 4 Weeks $0.2765 45.13% 2.97% 93.13% 4/3/25 4/4/25
CONY YieldMax™ COIN Option Income Strategy ETF Every 4 Weeks $0.4381 73.33% 4.42% 94.62% 4/3/25 4/4/25
CVNY YieldMax™ CVNA Option Income Strategy ETF Every 4 Weeks $2.9684 100.49% 2.44% 99.08% 4/3/25 4/4/25
FIAT YieldMax™ Short COIN Option Income Strategy ETF Every 4 Weeks $0.9240 127.21% 1.73% 98.90% 4/3/25 4/4/25
MSFO YieldMax™ MSFT Option Income Strategy ETF Every 4 Weeks $0.3337 27.09% 3.75% 0.00% 4/3/25 4/4/25
NFLY YieldMax™ NFLX Option Income Strategy ETF Every 4 Weeks $0.6020 46.77% 3.58% 59.10% 4/3/25 4/4/25
PYPY YieldMax™ PYPL Option Income Strategy ETF Every 4 Weeks $0.3521 34.34% 4.19% 0.00% 4/3/25 4/4/25
Weekly Payers & Group D ETFs scheduled for next week: GPTY LFGY QDTY RDTY SDTY ULTY YMAG YMAX AIYY AMZY APLY DISO MSTY SMCY XYZY YQQQ



Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted above. Performance current to the most recent month-end can be obtained by calling 

(833) 378-0717
.

Note: DIPS, FIAT,CRSH, YQQQ and WNTR are hereinafter referred to as the “Short ETFs.”

Distributions are not guaranteed. The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from period to period and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant.

Investors in the Funds will not have rights to receive dividends or other distributions with respect to the underlying reference asset(s).


1
All
YieldMax
™ ETFs shown in the table above (except

YMAX

,

YMAG

,

FEAT

,

FIVY

and

ULTY

) have a gross expense ratio of 0.99%.

YMAX

,

YMAG

and

FEAT

have a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.99% for a gross expense ratio of 1.28%.

FIVY

has a Management Fee of 0.29% and Acquired Fund Fees and Expenses of 0.59% for a gross expense ratio of 0.88%. “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other
YieldMax
™ ETFs.

ULTY 

has a gross expense ratio after the fee waiver of 1.30%. The Advisor has agreed to a fee waiver of 0.10% through at least February 28, 2026

.

2
The Distribution Rate shown is as of clo
se
on

April


1,


2025

.
The
Distribution Rate
is the annual
distribution rate
an investor would receive if the most recent distribution,

which includes option income

, remained the same going forward. The
Distribution Rate
is calculated by
annualizing
an ETF’s
Distribution per Share and dividing
such annualized
amount by the ETF’s most recent NAV. The
Distribution Rate
represents a single distribution from the ETF and does not represent its total return.
Distributions may also include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease
an ETF’s
NAV and trading price over time. As a result, an investor may suffer significant losses to their
investment. These Distribution Rates may be caused by unusually favorable market conditions and may not be
sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.

3
The 30-Day SEC Yield represents net investment income,

which excludes


option


income

,
earned by such ETF over the 30-Day period ended

March 31, 2025

, e
xpressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.

4
Each ETF’s strategy (

except those of the Short ETFs

) will cap potential gains if its reference
asset’s
shares increase in
value, yet
subjects an investor to all potential losses if the reference asset’s shares decrease in value. Such potential losses may not be offset by income received by the ETF.
Each

Short ETF’s

strategy will cap potential gains if its reference asset decreases in
value, yet
subjects an investor to all potential losses if the reference asset increases in value. Such potential losses may not be offset by income received by the ETF.

5
ROC refers to Return
of
Capital. The ROC percentage is the portion of the distribution that represents an investor’s original investment.
   

Each Fund has a limited operating history and while each Fund’s objective is to provide current income, there is no guarantee the Fund will make a distribution. Distributions are likely to vary greatly in amount.


Standardized Performance

For YMAX, click here. For YMAG, click here. For TSLY, click here. For OARK, click here. For APLY, click here. For NVDY, click here. For AMZY, click here. For FBY, click here. For GOOY, click here. For NFLY, click here. For CONY, click here. For MSFO, click here. For DISO, click here. For XOMO, click here. For JPMO, click here. For AMDY, click here. For PYPY, click here. For XYZY, click here. For MRNY, click here. For AIYY, click here. For MSTY, click here. For ULTY, click here. For YBIT, click here. For CRSH, click here. For GDXY, click here. For SNOY, click here. For ABNY, click here. For FIAT, click here. For DIPS, click here. For BABO, click here. For YQQQ, click here. For TSMY, click here. For SMCY, click here. For PLTY, click here. For BIGY, click here. For SOXY, click here. For MARO, click here. For FEAT, click here. For FIVY, click here. For LFGY, click here. For GPTY, click here. For CVNY, click here. For SDTY, click here. For QDTY, click here. For WNTR, click here.


Important Information

This material must be preceded or accompanied by the prospectus. For all prospectuses, click here.

Tidal Financial Group is the adviser for all YieldMax™ ETFs.

THE FUND, TRUST, AND ADVISER ARE NOT AFFILIATED WITH ANY UNDERLYING REFERENCE ASSET.


Risk Disclosures (applicable to all YieldMax ETFs referenced above,



except



the Short ETFs)

YMAX, YMAG, FEAT and FIVY generally invest in other YieldMax™ ETFs. As such, these two Funds are subject to the risks listed in this section, which apply to all the YieldMax™ ETFs they may hold from time to time.

Investing involves risk. Principal loss is possible.

Referenced Index Risk. The Fund invests in options contracts that are based on the value of the Index (or the Index ETFs). This subjects the Fund to certain of the same risks as if it owned shares of companies that comprised the Index or an ETF that tracks the Index, even though it does not.

Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way. Investors in the Fund will not have the right to receive dividends or other distributions or any other rights with respect to the companies that comprise the Index but will be subject to declines in the performance of the Index.

Russell 2000 Index Risks. The Index, which consists of small-cap U.S. companies, is particularly susceptible to economic changes, as these firms often have less financial resilience than larger companies. Market volatility can disproportionately affect these smaller businesses, leading to significant price swings. Additionally, these companies are often more exposed to specific industry risks and have less diverse revenue streams. They can also be more vulnerable to changes in domestic regulatory or policy environments.

Call Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s call writing strategy will impact the extent that the Fund participates in the positive price returns of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold call options and over longer periods.

Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings. A high portfolio turnover rate increases transaction costs, which may increase the Fund’s expenses.

Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

Price Participation Risk. The Fund employs an investment strategy that includes the sale of call option contracts, which limits the degree to which the Fund will participate in increases in value experienced by the underlying reference asset over the Call Period.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, which focuses on an individual security (ARKK, TSLA, AAPL, NVDA, AMZN, META, GOOGL, NFLX, COIN, MSFT, DIS, XOM, JPM, AMD, PYPL, SQ, MRNA, AI, MSTR, Bitcoin ETP, GDX®, SNOW, ABNB, BABA, TSM, SMCI, PLTR, MARA, CVNA), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.

Indirect Investment Risk. The Index is not affiliated with the Trust, the Fund, the Adviser, or their respective affiliates and is not involved with this offering in any way.


Risk Disclosures (applicable



only



to GPTY)

Artificial Intelligence Risk. Issuers engaged in artificial intelligence typically have high research and capital expenditures and, as a result, their profitability can vary widely, if they are profitable at all. The space in which they are engaged is highly competitive and issuers’ products and services may become obsolete very quickly. These companies are heavily dependent on intellectual property rights and may be adversely affected by loss or impairment of those rights. The issuers are also subject to legal, regulatory, and political changes that may have a large impact on their profitability. A failure in an issuer’s product or even questions about the safety of the product could be devastating to the issuer, especially if it is the marquee product of the issuer. It can be difficult to accurately capture what qualifies as an artificial intelligence company.

Technology Sector Risk. The Fund will invest substantially in companies in the information technology sector, and therefore the performance of the Fund could be negatively impacted by events affecting this sector. Market or economic factors impacting technology companies and companies that rely heavily on technological advances could have a significant effect on the value of the Fund’s investments. The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles, rapid product obsolescence, government regulation and competition, both domestically and internationally, including competition from foreign competitors with lower production costs. Stocks of information technology companies and companies that rely heavily on technology, especially those of smaller, less-seasoned companies, tend to be more volatile than the overall market. Information technology companies are heavily dependent on patent and intellectual property rights, the loss or impairment of which may adversely affect profitability.


Risk Disclosure (applicable



only



to MARO)

Digital Assets Risk: The Fund does not invest directly in Bitcoin or any other digital assets. The Fund does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. The Fund does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than the Fund. Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility.


Risk Disclosures (applicable



only



to BABO and TSMY)

Currency Risk: Indirect exposure to foreign currencies subjects the Fund to the risk that currencies will decline in value relative to the U.S. dollar. Currency rates in foreign countries may fluctuate significantly over short periods of time for a number of reasons, including changes in interest rates and the imposition of currency controls or other political developments in the U.S. or abroad.

Depositary Receipts Risk: The securities underlying BABO and TSMY are American Depositary Receipts (“ADRs”). Investment in ADRs may be less liquid than the underlying shares in their primary trading market.

Foreign Market and Trading Risk: The trading markets for many foreign securities are not as active as U.S. markets and may have less governmental regulation and oversight.

Foreign Securities Risk: Investments in securities of non-U.S. issuers involve certain risks that may not be present with investments in securities of U.S. issuers, such as risk of loss due to foreign currency fluctuations or to political or economic instability, as well as varying regulatory requirements applicable to investments in non-U.S. issuers. There may be less information publicly available about a non-U.S. issuer than a U.S. issuer. Non-U.S. issuers may also be subject to different regulatory, accounting, auditing, financial reporting, and investor protection standards than U.S. issuers.


Risk Disclosures (applicable



only



to GDXY)

Risk of Investing in Foreign Securities. The Fund is exposed indirectly to the securities of foreign issuers selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies. Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities.

Risk of Investing in Gold and Silver Mining Companies. The Fund is exposed indirectly to gold and silver mining companies selected by GDX®’s investment adviser, which subjects the Fund to the risks associated with such companies.

The Fund invests in options contracts based on the value of the VanEck Gold Miners ETF (GDX®), which subjects the Fund to some of the same risks as if it owned GDX®, as well as the risks associated with Canadian, Australian and Emerging Market Issuers, and Small-and Medium-Capitalization companies.


Risk Disclosures (applicable



only



to YBIT)

YBIT does not invest directly in Bitcoin or any other digital assets. YBIT does not invest directly in derivatives that track the performance of Bitcoin or any other digital assets. YBIT does not invest in or seek direct exposure to the current “spot” or cash price of Bitcoin. Investors seeking direct exposure to the price of Bitcoin should consider an investment other than YBIT.

Bitcoin Investment Risk: The Fund’s indirect investment in Bitcoin, through holdings in one or more Underlying ETPs, exposes it to the unique risks of this emerging innovation. Bitcoin’s price is highly volatile, and its market is influenced by the changing Bitcoin network, fluctuating acceptance levels, and unpredictable usage trends.

Digital Assets Risk: Digital assets like Bitcoin, designed as mediums of exchange, are still an emerging asset class. They operate independently of any central authority or government backing and are subject to regulatory changes and extreme price volatility. Potentially No 1940 Act Protections. As of the date of this Prospectus, there is only a single eligible Underlying ETP, and it is an investment company subject to the 1940 Act.

Bitcoin
ETP Risk: The Fund invests in options contracts that are based on the value of the Bitcoin ETP. This subjects the Fund to certain of the same risks as if it owned shares of the Bitcoin ETP, even though it does not. Bitcoin ETPs are subject, but not limited, to significant risk and heightened volatility. An investor in a Bitcoin ETP may lose their entire investment. Bitcoin ETPs are not suitable for all investors. In addition, not all Bitcoin ETPs are registered under the Investment Company Act of 1940. Those Bitcoin ETPs that are not registered under such statute are therefore not subject to the same regulations as exchange traded products that are so registered.


Risk Disclosures (applicable



only



to the Short ETFs)

Investing involves risk. Principal loss is possible.

Price Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the value of the underlying reference asset. This strategy subjects the Fund to certain of the same risks as if it shorted the underlying reference asset, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the value of the underlying reference asset, the Fund is subject to the risk that the value of the underlying reference asset increases. If the value of the underlying reference asset increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses.

Put Writing Strategy Risk. The path dependency (i.e., the continued use) of the Fund’s put writing (selling) strategy will impact the extent that the Fund participates in decreases in the value of the underlying reference asset and, in turn, the Fund’s returns, both during the term of the sold put options and over longer periods.

Purchased OTM Call Options Risk. The Fund’s strategy is subject to potential losses if the underlying reference asset increases in value, which may not be offset by the purchase of out-of-the-money (OTM) call options. The Fund purchases OTM calls to seek to manage (cap) the Fund’s potential losses from the Fund’s short exposure to the underlying reference asset if it appreciates significantly in value. However, the OTM call options will cap the Fund’s losses only to the extent that the value of the underlying reference asset increases to a level that is at or above the strike level of the purchased OTM call options. Any increase in the value of the underlying reference asset to a level that is below the strike level of the purchased OTM call options will result in a corresponding loss for the Fund. For example, if the OTM call options have a strike level that is approximately 100% above the then-current value of the underlying reference asset at the time of the call option purchase, and the value of the underlying reference asset increases by at least 100% during the term of the purchased OTM call options, the Fund will lose all its value. Since the Fund bears the costs of purchasing the OTM calls, such costs will decrease the Fund’s value and/or any income otherwise generated by the Fund’s investment strategy.

Counterparty Risk. The Fund is subject to counterparty risk by virtue of its investments in options contracts. Transactions in some types of derivatives, including options, are required to be centrally cleared (“cleared derivatives”). In a transaction involving cleared derivatives, the Fund’s counterparty is a clearing house rather than a bank or broker. Since the Fund is not a member of clearing houses and only members of a clearing house (“clearing members”) can participate directly in the clearing house, the Fund will hold cleared derivatives through accounts at clearing members.

Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. The Fund’s investments in derivatives may pose risks in addition to, and greater than, those associated with directly investing in securities or other ordinary investments, including risk related to the market, imperfect correlation with underlying investments or the Fund’s other portfolio holdings, higher price volatility, lack of availability, counterparty risk, liquidity, valuation and legal restrictions.

Options Contracts. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying reference asset, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events.

Distribution Risk. As part of the Fund’s investment objective, the Fund seeks to provide current income. There is no assurance that the Fund will make a distribution in any given period. If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

High Portfolio Turnover Risk. The Fund may actively and frequently trade all or a significant portion of the Fund’s holdings.

Liquidity Risk. Some securities held by the Fund, including options contracts, may be difficult to sell or be illiquid, particularly during times of market turmoil.

Non-Diversification Risk. Because the Fund is “non-diversified,” it may invest a greater percentage of its assets in the securities of a single issuer or a smaller number of issuers than if it was a diversified fund.

New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective investors do not have a track record or history on which to base their investment decisions.

Price Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will participate in decreases in value experienced by the underlying reference asset over the Put Period.

Single Issuer Risk. Issuer-specific attributes may cause an investment in the Fund to be more volatile than a traditional pooled investment which diversifies risk or the market generally. The value of the Fund, for any Fund that focuses on an individual security (e.g., TSLA, COIN, NVDA, MSTR), may be more volatile than a traditional pooled investment or the market as a whole and may perform differently from the value of a traditional pooled investment or the market as a whole.

Inflation Risk. Inflation risk is the risk that the value of assets or income from investments will be less in the future as inflation decreases the value of money. As inflation increases, the present value of the Fund’s assets and distributions, if any, may decline.


Risk Disclosures (applicable



only



to YQQQ)

Index Overview. The Nasdaq 100 Index is a benchmark index that includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, based on market capitalization.

Index Level Appreciation Risk. As part of the Fund’s synthetic covered put strategy, the Fund purchases and sells call and put option contracts that are based on the Index level. This strategy subjects the Fund to certain of the same risks as if it shorted the Index, even though it does not. By virtue of the Fund’s indirect inverse exposure to changes in the Index level, the Fund is subject to the risk that the Index level increases. If the Index level increases, the Fund will likely lose value and, as a result, the Fund may suffer significant losses. The Fund may also be subject to the following risks: innovation and technological advancement; strong market presence of Index constituent companies; adaptability to global market trends; and resilience and recovery potential.

Index Level Participation Risk. The Fund employs an investment strategy that includes the sale of put option contracts, which limits the degree to which the Fund will benefit from decreases in the Index level experienced over the Put Period. This means that if the Index level experiences a decrease in value below the strike level of the sold put options during a Put Period, the Fund will likely not experience that increase to the same extent and any Fund gains may significantly differ from the level of the Index losses over the Put Period. Additionally, because the Fund is limited in the degree to which it will participate in decreases in value experienced by the Index level over each Put Period, but has significant negative exposure to any increases in value experienced by the Index level over the Put Period, the NAV of the Fund may decrease over any given period. The Fund’s NAV is dependent on the value of each options portfolio, which is based principally upon the inverse of the performance of the Index level. The Fund’s ability to benefit from the Index level decreases will depend on prevailing market conditions, especially market volatility, at the time the Fund enters into the sold put option contracts and will vary from Put Period to Put Period. The value of the options contracts is affected by changes in the value and dividend rates of component companies that comprise the Index, changes in interest rates, changes in the actual or perceived volatility of the Index and the remaining time to the options’ expiration, as well as trading conditions in the options market. As the Index level changes and time moves towards the expiration of each Put Period, the value of the options contracts, and therefore the Fund’s NAV, will change. However, it is not expected for the Fund’s NAV to directly inversely correlate on a day-to-day basis with the returns of the Index level. The amount of time remaining until the options contract’s expiration date affects the impact that the value of the options contracts has on the Fund’s NAV, which may not be in full effect until the expiration date of the Fund’s options contracts. Therefore, while changes in the Index level will result in changes to the Fund’s NAV, the Fund generally anticipates that the rate of change in the Fund’s NAV will be different than the inverse of the changes experienced by the Index level.

YieldMax™ ETFs are distributed by Foreside Fund Services, LLC. Foreside is not affiliated with Tidal Financial Group, or YieldMax™ ETFs.

© 2025 YieldMax™ ETFs



Contact Gavin Filmore at [email protected] for more information.

First Foundation Inc. Announces First Quarter 2025 Earnings Conference Call Details

First Foundation Inc. Announces First Quarter 2025 Earnings Conference Call Details

DALLAS–(BUSINESS WIRE)–
First Foundation Inc. (NYSE: FFWM) (“First Foundation”), a financial services company with two wholly owned operating subsidiaries, First Foundation Advisors and First Foundation Bank, announced today that it will release its first quarter 2025 earnings results before the market opens on Wednesday, April 30, 2025.

At 11:00AM ET / 8:00AM PT on that same day, Chief Executive Officer Thomas C. Shafer of First Foundation will host a discussion of the Company’s financial results and performance and provide an update on recent activities.

First Foundation will announce the release via Business Wire, and the earnings report and slide presentation will be posted directly to First Foundation’s investor relations site.

Analysts, investors, and the general public may listen to a discussion of First Foundation’s quarterly earnings by using the information below:

Via Internet:

The call will be broadcast live over the Internet and can be accessed using the following link: First Foundation Q1 2025 Earnings Webcast or by visiting First Foundation’s website and clicking on “Investor Relations” and “Events & Presentations” https://investor.ff-inc.com/events-and-presentations/default.aspx.

Via Telephone (For those wishing to participate in the Q & A):

Participant Toll Free Dial-In Number: 800-715-9871

Conference ID: 2340475

It is recommended that participants dial into the conference call approximately ten minutes prior to the call.

ReplayInfo:

For those who are unable to participate during the live call, an archive of the call will be available for replay at http://investor.ff-inc.com/events-calendar.

About First Foundation

First Foundation Inc. (NYSE: FFWM) and its subsidiaries offer personal banking, business banking, and private wealth management services, including investment, trust, insurance, and philanthropy services. This comprehensive platform of financial services is designed to help clients at any stage in their financial journey. The broad range of financial products and services offered by First Foundation are more consistent with those offered by larger financial institutions, while its high level of personalized service, accessibility, and responsiveness to clients is more aligned with community banks and boutique wealth management firms. This combination of an integrated platform of comprehensive financial products and personalized service differentiates First Foundation from many of its competitors and has contributed to the growth of its client base and business. Learn more at firstfoundationinc.com or connect with us on LinkedIn and Twitter.

Investor contact: Jamie Britton, CFO, [email protected], (949) 476-0300

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Banking Professional Services Asset Management

MEDIA:

Logo
Logo